Endogenous antibody responses in REGN-COV2 treated SARS-CoV-2 infected individuals

Ashwini A Kurshan , Luke Blagdon Snell, Luke Blagdon Snell, Lucie Prior, Chung Him Jerry Tam, Carl Graham, Rajeni Thangarajah, Jonathan Edgeworth, Gaia Nebbia, Katherine Doores

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Neutralizing monoclonal antibodies (mAbs) targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein have been developed for the treatment of COVID-19. Whilst antibody therapy has been shown to reduce the risk of COVID-19-associated hospitalization and death, there is limited understanding of the endogenous immunity to SARS-CoV-2 generated in mAb-treated patients and therefore ongoing susceptibility to future infections. Here we measure the endogenous antibody response in SARS-CoV-2-infected individuals treated with REGN-COV2 (Ronapreve). We show that in the majority of unvaccinated, delta-infected REGN-COV2-treated individuals, an endogenous antibody response is generated, but, like untreated, delta-infected individuals, there was a limited neutralization breadth. However, some vaccinated individuals who were seronegative at SARS-CoV-2 infection baseline and some unvaccinated individuals failed to produce an endogenous immune response following infection and REGN-COV2 treatment demonstrating the importance of mAb therapy in some patient populations.

Original languageEnglish
Article numberiqac012
JournalOxford Open Immunology
Issue number1
Publication statusPublished - 2023


Dive into the research topics of 'Endogenous antibody responses in REGN-COV2 treated SARS-CoV-2 infected individuals'. Together they form a unique fingerprint.

Cite this